Tuesday, September 12, 2017

Hating on Antipsychotics: Are We Going Too Far?

Antipsychotics are not perfect. No drugs are. They can cause weight gain and weird movement side effects and sleepiness. But they have their uses, such as quelling racing thoughts, inner turmoil, and psychosis. There’s nothing inherently good or bad about any class of drugs. It’s up to physicians to understand the data and to prescribe medications judiciously.

With that introduction out of the way, let me describe for you a recent study that was published in the July 11 issue of JAMA. It’s called the VAST-D trial, which stands for “VA Augmentation and Switching Treatments for Improving Depression Outcomes”. In this study, researchers randomly assigned 1522 patients to thee treatments: 1. Switch from the current antidepressant to bupropion; 2. Continue the current antidepressant, and add bupropion; 3. Continue the current antidepressant and add aripiprazole (a second-generation antipsychotic that is FDA approved for adjunctive use in depression). (By the way, the study was not funded by aripiprazole’s makers, and the medication is now available in a low cost generic form).

 After 12 weeks of treatment, the aripiprazole augmentation group fared somewhat better than the others:
Outcome at 12 weeks
Aripiprazole augmentation
Bupropion augmentation
Bupropion switch
Remission rate
29% (statistically superior to bup switch)
Response rate
74% (statistically superior to bup switch and augmentation)

Aripiprazole augmentation yielded a higher remission rate than switching to bupropion, and it produced a higher response rate than either one of the bupropion strategies. But let’s look at side effects—some were more common in the aripiprazole group, others in the bupropion group. Side

Effects Statistically More Common in the Aripiprazole Group:

Side Effects
Aripiprazole augmentation
Bupropion augmentation
Bupropion switch
Weight increased by at least 7% at 12 weeks
Weight increased by at least 7% at 36 weeks

Side Effects Statistically More Common in the Bupropion Groups:

Side Effects
Aripiprazole augmentation
Bupropion augmentation
Bupropion switch

Basically, bupropion caused more anxiety and tremor, while aripiprazole caused more weight gain, tiredness, and akathisia (a feeling of inner restlessness often caused by antipsychotics). Now, although aripiprazole caused more side effects, patients seemed to be less bothered by these side effects than those in the other treatment groups—at least as measured by the percentage of patients who withdrew from the study due to side effects. Only 5.3% of the aripiprazole patients withdrew because of side effects, as opposed to 7.3% in the bupropion augmentation group, and 10% in the bupropion switch group.

If you want to quibble with the results, there are a lot of details about the study that you can pick apart. And as is true for just about any large study, these would be reasonable points. But for me as a clinician, the bottom line is that this is the first large truly randomized study comparing antipsychotic augmentation with two other very common strategies for patients who don’t respond to the first antidepressant. And the results pretty clearly show that aripiprazole augmentation is somewhat more effective than the two other methods tested. This doesn’t mean that suddenly all my patients are going to be on aripiprazole. A quarter of patients had significant weight gain after 9 months, and about 15% had akathisia. Those can be problems, but in clinical practice, you monitor for side effects, and if they are bad, you stop the offending medication and try something else. That’s a risk/benefit decision . . . and this study implies that aripiprazole should be high on your options for treatment resistant depression.

But here’s the thing: Nobody seems to want to admit that it works.

 On Medpage Today’s Slow Medicine blog, the focus was on the side effects of aripiprazole, and how this study will definitely not convince them to use aripiprazole.

 Their commentary was titled “No Atypical Antipsychotics for Depression,” and they concluded with: “In the face of uncertainty, our Slow Medicine philosophy favors the safer, more conservative approach. VAST-D will not change our practice. Until we see clear evidence of benefits that outweigh the harms, we don't see a role for antipsychotics for most patients with depression. For now, among patients with an inadequate response to a first antidepressant, we'll try a second antidepressant, consider enhancing behavioral therapy, or think about augmenting with the safer medication, buproprion.”

Given that their philosophy is to avoid quick fixes and take a cautious approach to new treatments, I can understand this coming from Slow Medicine. But even the authors of the original JAMA article took pains to downplay the results. Here’s their conclusion:

 “Among a predominantly male population with major depressive disorder unresponsive to antidepressant treatment, augmentation with aripiprazole resulted in a statistically significant but only modestly increased likelihood of remission during 12 weeks of treatment compared with switching to bupropion monotherapy. Given the small effect size and adverse effects associated with aripiprazole, further analysis including cost-effectiveness is needed to understand the net utility of this approach.”

Really? First, they’re reminding us that we can’t generalize the results beyond the population studied (okay, we got that, it is, after all, a study of vets). Second, they are pretending that response rate was not one of the pre-specified outcome variables (it was a secondary outcome, but based on the same depression scale used for the primary outcome), and therefore they are making believe that there’s no evidence that aripiprazole was better than bupropion augmentation, not just better than switching. And finally, there’s this bizarre indirect way of saying “these results are unimpressive, don’t change your practice.” (I guess that’s what they mean by “net utility”).

 Dudes, this was a major study, and you got an interesting, clinically relevant, result!

It’s okay to brag a little. Let’s go where the data take us, even if we’ve become accustomed to hating on the drugs that come out on top.

Wednesday, September 6, 2017

We're Diagnosing Like It's 1799

The fact that psychiatry lags far behind the rest of medicine scientifically is no great news flash. The leaders of our field have long acknowledged this problem (see, for example, this withering self-critique by then head of NIMH Thomas Insel).  None of this should be taken personally. Psychiatrists are just as smart as other doctors. It’s just that we have the misfortune of having chosen the most complicated organ to study—the brain.

Nonetheless, occasionally I come across information that reminds me anew of just how far in the dark ages we are stuck. This happened a couple of weeks ago when I was binge-listening to podcasts and happened upon this great episode of the 99% invisible podcast about the origin of the stethoscope.

The stethoscope was invented in 1816 by a 35 year old Parisian physician, René Laennec. Laennec was particularly interested in “diseases of the chest” as they were called then, and especially tuberculosis, which was ravaging Paris and had a 50% death rate. Doctors knew a little bit about how TB affected the lungs based on autopsy findings. But they didn’t have clue that what caused it (that would have to wait until 1882 when Robert Koch discovered mycobacterium tuberculosis), and they had a very hard time diagnosing the disease in a living person. TB causes symptoms such as dyspnea (shortness of breath), coughing up blood, weight loss, and fever, but many patients with other diseases presented similarly. Doctors had no diagnostic tools or blood tests, and depended on having long talks with patients about their symptoms and history. But conversations about an illness only got them so far, and commonly the final diagnosis was simply “dyspnea” or “fever”—which we now know are symptoms with various underlying causes, but which in the 18th century were thought of as diseases.

A medical transformation was borne one day when Dr. Laennec was examining an overweight woman with dyspnea. Based on their conversation, Laennec could not distinguish TB, pneumonia, or heart disease. He tried chest percussion, a popular method that helps detect whether areas of the lung are filled with inflammatory fluid, but the abundance of tissue rendered that technique unhelpful. He was tempted to simply place his ear on her chest—a technique called “immediate auscultation,” but felt that it was “indelicate” to do so. He looked around and, in his words, “grabbed 24 sheets of paper, rolled them tightly into a bundle, and secured them in shape with paste glue.” Using this cylinder, he placed one end onto her chest, and other to his ear.  He was “delighted” to find that he could hear heart and breath sounds with amazing clarity.

Laennec refined the device over the next several years, hiring a carpenter to build better versions out of wood, and he shared his discovery with colleagues. Armed with the stethoscope, doctors carefully correlated breath and heart sounds of dying patients with autopsy findings, eventually reporting a series of “pathognomonic” sounds that could, with a good degree of certainty, diagnose specific diseases. Whereas patients were once told that their disease was “dyspnea,” they could now learn which organ was affected, and what the likely prognosis was. Unfortunately, effective treatment had to wait for the discovery of antibiotics and cardiac drugs.

In psychiatry, diagnostically we are squarely in the pre-Laennec era (though therapeutically, we have serendipitously discovered highly effective treatments for many disorders). We diagnose such entities as “major depression” and “schizophrenia” based on prolonged conversations with patients, conversations termed “mental status exams.” We combine our observations with the history to discover clusters of symptoms that often occur together, and which are therefore included as “disorders” in the DSM-5. But, like physicians in 1799, we don’t understand how the pathology of the underlying organ leads to these symptoms. In fact, our science is arguably considerably more primitive than 1799 medicine, because even our autopsy results have not identified any lesions responsible for psychiatric symptoms—with the exception of Alzheimer’s disease.

Psychiatry does not have a stethoscope. We have ancillary technologies, such as MRIs, PET scans, EEGs, and blood tests, all of which can effectively rule out other diseases that can mimic psychiatric disorders. But we can’t peer into our patient’s brain to tell them what lesion or circuit mishap causes them to suffer as they do.

We need to acknowledge that a careful interview is not only central to psychiatric diagnosis, but is the only method we currently have in our diagnostic tool box. If we really want to help our patients, we need to enhance our skills at asking the right questions and understanding the meanings of the answers. Which may well take more time than insurance companies believe we are worth.

Tuesday, August 29, 2017

Ecstasy for PTSD: Some Background

You may have heard that the Food and Drug Administration has given the drug ecstasy (MDMA) its "breakthrough designation" for the treatment of PTSD. See this very thoughtful article in the Washington Post for details. 

I came out of blog-slumber to post about this because we're in the midst of planning an upcoming issue of TCPR (The Carlat Psychiatry Report) on PTSD, and because we've recently published a fair amount of material about MDMA. 

First, here's why we need better PTSD treatments. Only two drugs are FDA approved for PTSD: Paxil and Zoloft. Neither are very effective. In the original FDA trials, the drugs beat placebo but not by much; in fact, about 80% of the drug's efficacy is likely due to placebo factors. (See an older issue of TCPR for more on these trials). Various other drugs are used off label, such as Prazosin which helps with insomnia and nightmares, atypical antipsychotics, and alpha agonists such as clonidine and guanfacine. 

Psychotherapy is more effective than drugs, though the treatments most validated are imperfect and are variations of exposure therapy. Patients are asked to recount the trauma over and over again until they are desensitized to the anxiety elicited by the memory. The problem is that this process is emotionally painful and many patients just can't bear the idea of having to recall their trauma (such as a rape, a military attack, or a natural catastrophe) repetitively. 

Enter MDMA. Last March we published an issue of CATR (The Carlat Addiction Treatment Report) on psychiatric uses of street drugs. Psychiatrist Philip Wolfson wrote an overview of the many therapeutic uses of hallucinogens and other substances (full article here), and we interviewed the training project manager of the MDMA/PTSD research program, Shannon Clare Petitt (full interview here). I've reproduced a portion of Petitt's interview at the end of my post below. These are clearly boom times for those seeking creative ways to repurpose "recreational" drugs for healing purposes. In my opinion, that's a good thing for psychiatry, as we have been in something of a pharmacological rut for many years now. 

Excerpt from "MDMA-Assisted Psychotherapy for Posttraumatic Stress Disorder", an interview with Shannon Clare Petitt, MA, first published in The Carlat Addiction Treatment Report, Vol 5, No. 2, March/April 2017. Ms. Petitt is the MDMA therapy training program manager at MAPS Public Benefit Corporation (MPBC), Santa Cruz, CA.
CATR: You work for MPBC, MAPS Public Benefit Corporation, a subsidiary of the Multidisciplinary Association for Psychedelic Studies, as MDMA therapy training program manager. What does your work involve?
S. Petitt: My work is focused on managing the program that selects and trains researchers for the MDMA-assisted psychotherapy protocols MPBC is conducting. As you might imagine, it’s important to select applicants who have experience working with trauma and are truly well suited for MDMA-assisted psychotherapy. Over the past year, we have reviewed 300 applicants, and right now we are in the midst of training 80 people who will work on therapy teams for Phase 3 trials. In addition to the training program, I also served as co-therapist on the MAPS-sponsored Phase 2 trial of MDMA-assisted psychotherapy for anxiety associated with life-threatening illness.
CATR: Most people know MDMA as “ecstasy,” a drug of abuse. How does it assist in psychotherapy?
S. Petitt: We have two main hypotheses that drive our research. The first is that MDMA reduces activity in the amygdala, which is the fear center of the brain. This is supported by animal research showing MDMA facilitates fear extinction learning. This is important because the hallmark of PTSD is reexperiencing—feeling as though the traumatic experience that happened in the past is actually happening in the present moment. MDMA allows people to recall traumatic memories without the same fear response, and of course this makes it much easier to process and recontextualize those memories.
CATR: It sounds like MDMA helps make recalling traumatic memories less aversive. What’s the second hypothesis?
S. Petitt: It’s relational. Working with trauma is about establishing trust and safety, and MDMA facilitates that.
CATR: In what way?
S. Petitt: MDMA is not a classic psychedelic that induces hallucinations or distortions. It’s better described as an empathogen, or some people call it an entactogen, because it produces feelings of compassion for oneself and others and helps establish trust. It’s so effective in this area that it was actually used in couples therapy before it became illegal in the U.S.

Friday, February 17, 2017

Antidepressant News: Just the Right Amount of Opiate?

In the early 1950s, opium was considered an effective treatment for depression, but gradually it fell out of favor as its addiction risk became clear. Nonetheless, there's no denying that opioids rapidly elevate the mood of just about anybody, even the very depressed. So that's a pretty tantalizing challenge: Is it possible to harness the elating effects of opiates while avoiding the addictive "side effects," as it were.

source: amrismartsourcing.com
A recent contender is a drug made by Alkermes code named ALKS 5461. This drug is a combination of buprenorphine and samidorphan. Buprenorphine is an opioid which is often combined with naltrexone to produce drugs for opioid use disorder, such as Suboxone. Samidorphan is a derivative of naltrexone, and it doesn't antagonize opioid receptors quite as avidly as its cousin. So combining these two might just allow enough opioid receptor stimulation to squeeze through to treat depression, without it being too appealing to potential addicts.

Early phase I and phase II clinical trials with small numbers of subjects were promising. Based on these results, the company conducted larger phase III trials, called the FORWARD (Focused On Results With A Rethinking of Depression) trials. Unfortunately, the first two of the larger trials failed, showing no improvement over placebo. The third trial (FORWARD-5) was more successful. In that trial, 407 patients with depression unresponsive to a trial of standard antidepressants were randomized to receive ALKS 5461 as an adjunct, or placebo as an adjunct. The company reports that patients receiving the higher dose of 2mg of ALKS 5461 did significantly better than placebo, as measured by the MADRS rating scale. Side effects were nausea, dizziness, and fatigue.

Will this drug see the light of day? It’s unclear, but according to pharmaceutical industry news sources, Alkermes has been talking up its latest results with the FDA and hopes to get approval at some point within a year or two. It sure would be nice to have another antidepressant at our disposal.

Wednesday, September 7, 2016

Have Companies Stopped Ghostwriting? BMJ Article Says "No"

A new article in the British Medical Journal (BMJ) by Alastair Matheson takes a fresh look at ghostwriting in medical research. Apparently, pharmaceutical companies are waging a campaign to convince us that they are now opposed to ghostwriting. But Matheson argues that the practice continues, only under a different name: "editorial assistance."

It comes down to how we define ghostwriting. The standard definition in the Oxford dictionary is straightforward: a ghostwriter is “a person whose job it is to write material for someone else who is the named author."

If a company recruits academics to put their names on a paper, but then pays an unnamed medical writer to actually compose the paper, that's clearly ghostwriting and is a deceptive practice. But it's rarely so straightforward. Yes, companies recruit academics to help design, conduct, and write research studies. Yes, companies also hire medical writers to do the grunt work of writing up the results of a study. Typically, medical writers are acknowledged in small print in the footnotes. Companies are claiming that this acknowledgment means they are being honest, and properly informing readers that these non-academics also contributed to the paper. Therefore, they are innocent of ghostwriting.

Matheson disagrees, arguing that these medical writers do a lot more than just the tedious rendering of the methods and results of research. Instead, they work closely with the funding companies to shape the manuscript in such a way that the funded drug looks good. The identified authors, whose names are in lights just below the title, may indeed edit and review the paper before publication, but the companies have plenty of leverage over the final content.

Simply publishing a footnoted acknowledgment of a medical writer for "editorial assistance" is not enough, he says, because it covers up a process in which the company uses the medical writer as a conduit to spin the paper in a commercial way. The solution? The International Committee of Medical Journal Editors (ICMJE) should require that any writer who contributes to the manuscript should be listed as an official author. He points out that the journal Neurology already has this policy in place, and indeed, if you look up their authorship policy here, you'll find the following crystal clear statement:

"Professional writers employed by pharmaceutical companies or other academic, governmental, or commercial entities who have drafted or revised the intellectual content of the paper must be included as authors."

Furthermore, Matheson calls for ICMJE to develop other rules to prevent what he calls "attributional spin." For example, in deciding the order of the listed authors, those with the most actual influence over content (often the employees of the company) should be listed first, rather than being listed after the academics as is sometimes done.

It's a good read. The article piqued my curiosity because over the last few days I've been slogging through the literature on antidepressant-induced sexual dysfunction to write an article for the next issue of the Carlat Psychiatry Report. Most of the articles are industry funded, and all of them relegate mention of medical writers to footnotes.

For example, here's page 1 of one of the studies I've read. There are five authors, the first of whom is an independent academic, and the last four are employees of vilazodone's maker Forest.

And here's the last page of the paper, which acknowledges Adam Ruth, a medical writer, for "writing assistance and editorial support."

According to Matheson, Adam Ruth should be listed as an author. I agree.

It's true that in this particular case, you could argue that Forest is already being transparent enough by clearly stating that four of  the authors are company employees. Nonetheless, adding the medical writer as an author reminds the reader that industry funded articles are essentially commercial, rather than academic enterprises. Maybe that's obvious, but sometimes it's worth stating the obvious.

Monday, October 5, 2015

Boston Globe Article about Genetic Testing in Psychiatry

It would be fantastic to have a lab test to help us decide which drugs to prescribe in psychiatry. See Sunday's great Boston Globe article that picked up on our recent coverage of the GeneSight test

It's a promising technology, but the marketing has leap-frogged ahead of the science. 

This Wednesday afternoon I will be participating in a webcast with journalists and other doctors about this controversial issue. 

The chat will begin this Wednesday, 10/7, from 3:30 p.m. to 4:30 p.m. The conversation will appear in the embed below and on the New England Center for Investigative reporting page here. You can start submitting questions now though.

Live Blog What should you know about psychiatric genetic testing?

Wednesday, September 16, 2015

The TMS Wars: Psychiatry Goes High Tech

In the pages of The Carlat Psychiatry Report, we’ve covered transcranial magnetic stimulation (TMS) numerous times—most recently in the current issue. For those who haven’t heard of these devices, they work by pulsing magnetic fields into the brain. The magnetic fields stimulate neurons—far more gently than electroconvulsive therapy. The theory is that this gentle brain stimulation, focused on specific brain regions, eases depression.

After skeptically covering this technology for almost a decade, I’m finally convinced that it actually works.  A recent systematic review, funded by the U.S. Government and written by authors with no ties to any TMS company, endorsed the technology pretty strongly. They found that for patients who were treatment resistant (those who had not responded to at least two antidepressants), TMS was three times as effective as the sham (placebo) control group.

Admittedly, it’s a little creepy and science-fictiony that we are in an era when magnetic stimulators are actually effective for changing our moods. But so be it.

Now that we have an effective device in psychiatry, it’s kind of fun to see these manufacturers competing for market share. There are already two TMS devices on the market: NeuroStar and Brainsway.

Over the past couple of months, two new companies have jumped into the fray. I received this letter from a company called Magstim, announcing their new Rapid 2 Therapy System. Without going into too many technical details, this device, as you can see below, looks like a glorified dental chair with a sleek brain stimulator attached.


MagVita is an even newer device, just approved last month.

As is turns out, these two upstarts are threatening to shake the nascent TMS industry to its core. Why? Because they are entering the market with an offer that’s almost impossible to refuse: no per-use fee. Both Neurostar and Brainsway charge a bundle of money up front to buy or lease the device, then they charge an extra $100 or so per treatment for disposable “shields” which aren’t actually necessary. They are simply income generators.

Magstim and MagVita are chucking those shields—saving doctors thousands of dollars in pointless charges.

What does this mean for patients? Probably that the treatments will be more affordable—more insurers will cover the cheaper Magstim and MagVita devices, and patients who must pay out of pocket will have less sticker shock. And what does this mean for Neurostar and Brainsway? Lots of anxiety, and deep discounts to try to keep up with Magstim and MagVita.

Want to learn more about neurostimulation devices? 
The July/August issue on “Interventional Psychiatry” offers an overview of this fast-changing world and is available as an individual purchase which includes 2 category 1 CME credits.
  • Summary of neurostimulation methods, including: transcranial magnetic stimulation (TMS), magnetic seizure therapy (MST), vagus nerve stimulation (VNS), transcutaneous vagal nerve stimulation (tVNS), transcranial direct current stimulation (tDCS).
  • Expert Q&A on the past and future of TMS with Dr. Mark George of the Brain Stimulation Laboratory at the Medical University of South Carolina.
  • Expert Q&A on what it means to be an "interventional psychiatrist" with Dr. Nolan Williams of Stanford University.
  • Review of the Fisher Wallace and Alpha-Stim devices as treatment options for depression.
  • A practical guide on which TMS device you should buy (if any) for your practice.